AI Article Synopsis
- - Alcohol use disorders contribute significantly to global health issues, and current treatments are limited, sparking interest in the medication semaglutide for potential benefits in reducing alcohol consumption.
- - A study reviewing health records of 83,825 obese patients found that those treated with semaglutide had a 50%-56% lower risk of developing or relapsing into alcohol use disorders over 12 months compared to those on other weight loss medications.
- - The positive effects of semaglutide were consistent across different demographics and were supported by similar results in a larger group of 598,803 patients with type 2 diabetes, suggesting a need for further clinical trials to explore these findings.
Article Abstract
Alcohol use disorders are among the top causes of the global burden of disease, yet therapeutic interventions are limited. Reduced desire to drink in patients treated with semaglutide has raised interest regarding its potential therapeutic benefits for alcohol use disorders. In this retrospective cohort study of electronic health records of 83,825 patients with obesity, we show that semaglutide compared with other anti-obesity medications is associated with a 50%-56% lower risk for both the incidence and recurrence of alcohol use disorder for a 12-month follow-up period. Consistent reductions were seen for patients stratified by gender, age group, race and in patients with and without type 2 diabetes. Similar findings are replicated in the study population with 598,803 patients with type 2 diabetes. These findings provide evidence of the potential benefit of semaglutide in AUD in real-world populations and call for further randomized clinicl trials.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11133479 | PMC |
| http://dx.doi.org/10.1038/s41467-024-48780-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!